BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 7923984)

  • 1. Hemodialysis using high flux membranes improves lipid profiles.
    Blankestijn PJ
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S48-51. PubMed ID: 7923984
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes.
    Floege J; Koch KM
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S52-6. PubMed ID: 7923985
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term experience with high-flux polysulfone in hemodialysis.
    Civati G; Teatini U; Guastoni C; Perego A; Perrino ML; Ballerini L; Minetti L
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S26-30. PubMed ID: 7923979
    [No Abstract]   [Full Text] [Related]  

  • 4. Are biocompatible membranes superior for hemodialysis therapy?
    van Ypersele de Strihou C
    Kidney Int Suppl; 1997 Nov; 62():S101-4. PubMed ID: 9350694
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical evaluation of the new, steam-sterilized polysulfone high-flux dialyzer.
    Schaefer RM; Kulzer P; Gilge U; Schaefer L; Heidland A
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S21-5. PubMed ID: 7923978
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients.
    Klemm A; Sperschneider H; Winnefeld K; Günther K; Stein G
    Clin Nephrol; 1997 Feb; 47(2):133-4. PubMed ID: 9049466
    [No Abstract]   [Full Text] [Related]  

  • 7. Phosphate removal during dialysis--does the membrane matter?
    Ritz E
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S57-60. PubMed ID: 7923986
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased soluble CD14 levels in patients on hemodialysis. Influence of dialysate endotoxin or incompatibility to dialyzer membranes?
    Mitzner S; Stange J; Pichel K; Handschuk I; Korten G; Ehlers M; Schutt C; Schmidt R
    ASAIO J; 1995; 41(3):M707-8. PubMed ID: 8573897
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical experience with polysulfone: 10 years.
    Vanholder R; Van Loo A; Ringoir S
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S13-20. PubMed ID: 7923977
    [No Abstract]   [Full Text] [Related]  

  • 10. All high-flux membranes are equal but some high-flux membranes are less equal than others.
    Vanholder R; Pedrini LA
    Nephrol Dial Transplant; 2008 May; 23(5):1481-3. PubMed ID: 18305315
    [No Abstract]   [Full Text] [Related]  

  • 11. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.
    Thalhammer F; Rosenkranz AR; Burgmann H; Graninger W; Hollenstein U; Schenk P; Thalhammer-Scherrer R; Traindl O; Hörl WH; Breyer S
    Wien Klin Wochenschr; 1997 May; 109(10):362-5. PubMed ID: 9200809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo assessment of intact parathyroid hormone adsorption by different dialysis membranes during hemodialysis.
    Balducci A; Coen G; Manni M; Perruzza I; Fassino V; Sardella D; Grandi F
    Artif Organs; 2004 Dec; 28(12):1067-75. PubMed ID: 15554934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biocompatibility in long-term hemodialysis: facts--theories--clinical significance].
    Bosch TH; Blumenstein M; Gurland HJ
    Z Urol Nephrol; 1989 Feb; 82(2):69-76. PubMed ID: 2658418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mortality in patients with chronic renal insufficiency undergoing hemodialysis. Hyperlipemia as coadjuvant factor].
    Joven J; Vilella E; Brunzell JD
    Med Clin (Barc); 1991 Jan; 96(3):110-3. PubMed ID: 2033971
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of high-flux hemodialysis on renal anemia.
    Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
    J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes.
    Krieter DH; Lemke HD; Wanner C
    Nephrol Dial Transplant; 2006 Feb; 21(2):546; author reply 546. PubMed ID: 16249195
    [No Abstract]   [Full Text] [Related]  

  • 17. Advances and innovations in dialysis in the 21st century.
    Power A; Duncan N; Goodlad C
    Postgrad Med J; 2009 Feb; 85(1000):102-7. PubMed ID: 19329705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The technical evolution of hemodialysis].
    Man NK; Crosnier J
    Ann Med Interne (Paris); 1973 Feb; 124(2):81-4. PubMed ID: 4723745
    [No Abstract]   [Full Text] [Related]  

  • 19. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
    Kes P; Reiner Z; Brunetta B
    Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of cellulose diacetate dialysis membranes on lipids and lipoproteins in uremic patients].
    Jakić M; Rupcić V; Stipanić S; Samardzija G; Bilandzija M; Zibar L; Mihaljević D; Milas J
    Lijec Vjesn; 1997 Feb; 119(2):56-9. PubMed ID: 9297037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.